Paratek Pharmaceuticals, Inc. Reports First Quarter 2017 Financial Results and Provides Clinical Update
Reported positive Phase 3 study results with omadacycline in community-acquired bacterial pneumonia (CABP) Updated timing to submit regulatory application with U.S. FDA to as early as first quarter 2018 Conference call scheduled for 8:30 a.m. EDT on …